One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The voices of lived experience in diabetes and endocrinology
doi : 10.1016/S2213-8587(23)00008-6
Volume 11, Issue 2, February 2023, Page 63
ORION-3: delivering lipid lowering treatment for longer
doi : 10.1016/S2213-8587(22)00362-X
Volume 11, Issue 2, February 2023, Pages 67-68
Blood lipids after COVID-19 infection
doi : 10.1016/S2213-8587(22)00389-8
Volume 11, Issue 2, February 2023, Pages 68-69
Insulin products and patents in the USA in 2004, 2014, and 2020: a cross-sectional study
doi : 10.1016/S2213-8587(22)00354-0
Volume 11, Issue 2, February 2023, Pages 73-75
Analysis of cluster randomised trials as if they were individually randomised
doi : 10.1016/S2213-8587(22)00363-1
Volume 11, Issue 2, February 2023, Page 75
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply
doi : 10.1016/S2213-8587(22)00361-8
Volume 11, Issue 2, February 2023, Pages 75-76
Teplizumab approval for type 1 diabetes in the USA
doi : 10.1016/S2213-8587(22)00390-4
Volume 11, Issue 2, February 2023, Pages 76-77
Teplizumab approval for type 1 diabetes in the USA
doi : 10.1016/S2213-8587(22)00391-6
Volume 11, Issue 2, February 2023, Pages 77-78
Teplizumab approval for type 1 diabetes in the USA
doi : 10.1016/S2213-8587(22)00384-9
Volume 11, Issue 2, February 2023, Pages 78-80
May Ng: a lifetime commitment to children
doi : 10.1016/S2213-8587(23)00003-7
Volume 11, Issue 2, February 2023, Page 81
Hot topics on insulin access: pricing in the USA
doi : 10.1016/S2213-8587(23)00006-2
Volume 11, Issue 2, February 2023, Pages 82-84
Diabetes educators: rewriting the narrative
doi : 10.1016/S2213-8587(23)00007-4
Volume 11, Issue 2, February 2023, Page 85
Correction to Lancet Diabetes Endocrinol 2022; 10: 859–68
doi : 10.1016/S2213-8587(22)00360-6
Volume 11, Issue 2, February 2023, Page e2
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
doi : 10.1016/S2213-8587(22)00353-9
Volume 11, Issue 2, February 2023, Pages 109-119
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study
doi : 10.1016/S2213-8587(22)00355-2
Volume 11, Issue 2, February 2023, Pages 120-128
Glucagon, from past to present: a century of intensive research and controversies
doi : 10.1016/S2213-8587(22)00349-7
Volume 11, Issue 2, February 2023, Pages 129-138
